NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Of ...

Arvinas与Novartis达成交易 - Arvinas与Novartis达成了价值超过10亿美元的交易[1] - Novartis将向Arvinas支付1.5亿美元作为前期费用，并获得其第二代前列腺癌治疗药物ARV-766的独家许可[2] - Arvinas有资格获得另外10.1亿美元的“开发、监管和商业里程碑”以及ARV-766销售的版税[4] Arvinas与Novartis合作 - Arvinas首席执行官表示，Novartis的专业知识和规模将拓展ARV-766的开发，并有望成为前列腺癌患者的一流治疗方案[3] Arvinas股票表现 - Arvinas股票自2月中旬年初以来下跌超过15%[3] Stifel分析师评级 - Stifel分析师重申对Arvinas股票的“买入”评级，并将目标股价上调至72美元，暗示股价有望上涨90%[8] Novartis股票表现 - Novartis股票在Arvinas新闻公布后下跌近1.0%[9]

– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties – – Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 – – Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for ...

One stock that might be an intriguing choice for investors right now is Arvinas, Inc. (ARVN) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in ...

人事变动 - Arvinas, Inc.宣布任命Noah Berkowitz博士为首席医学官[1] - Noah Berkowitz博士将领导Arvinas的PROTAC®蛋白降解剂项目在肿瘤学和神经科学领域的持续临床开发[2] - Berkowitz博士在临床开发、监管和医学事务方面拥有超过20年的经验，此前曾在Bristol-Myers Squibb（BMS）担任高级副总裁[3] - Ron Peck博士将离开Arvinas，Noah Berkowitz博士将接替其职务[5] - Arvinas授予Noah Berkowitz博士购买93,879股普通股的期权和63,452股普通股的限制性股票单位奖励[6] 公司信息 - Arvinas是一家临床阶段的生物技术公司，致力于通过发现、开发和商业化降解致病蛋白的疗法来改善患有严重疾病的患者的生活[8] 风险提示 - Arvinas的前瞻性声明包含了大量风险和不确定性，包括与Arvinas的发展计划、首个Phase 3临床试验数据的预期等相关内容[9]

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences: Leerink Partners Global Biopharma Conference on Tuesday, March 12. Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D., interim chief financial officer, will participate in a fireside chat. A live audio webcast of the presen ...

Investors are always looking for stocks that are poised to beat at earnings season and Arvinas, Inc. (ARVN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Arvinas is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicat ...

Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -90.23%. A quarter ago, it was expected that this company would post a loss of $1.52 per share when it actually produced a loss of $1.18, delivering a surprise of 22.37%.Over the last four quarters, the company has surpassed ...

临床研究 - 全球多个临床研究中继续招募参与者，包括第二线设置中的VERITAC-2第3期试验和VERITAC-3第3期试验的前期研究[1] - 新的第3期试验计划将包括与CDK4/6抑制剂联合应用的新的第3期试验，以及与辉瑞的新型CDK4抑制剂联合应用的第一线设置中的新的第3期试验[1] - 优先考虑第二代PROTAC® AR降解剂ARV-766，因为更新的数据显示在mCRPC中所有AR LBD突变的肿瘤中具有强大的疗效[1] - 获得监管机构批准，启动针对BCL6的PROTAC®和针对LRRK2的第一个神经科学PROTAC®降解剂的首个人类第1期临床试验[1] 财务业绩 - 完成了截至2023年12月31日的第四季度和全年的财务业绩报告，并提供了公司更新[1] - 2023年的专注执行使公司得以推进整个产品组合的多个试验，并为未来的丰富里程碑做好了准备[2] 临床试验结果 - 在2023年圣安东尼奥乳腺癌研讨会上展示了vepdegestrant和palbociclib联合队列的中期结果，显示在局部晚期或转移性ER+/HER2-乳腺癌患者中具有鼓舞人心的临床活性[3] - 在可评估患者中，具有可测疾病的客观反应率为42%，持续反应的中位时间为10.2个月[4] 公司合作 - Arvinas与辉瑞达成全球合作协议，共同开发和共同商业化vepdegestrant，双方将平均分担全球开发成本、商业化费用和利润[36] - 与辉瑞的合作保持强劲，计划报告首个使用vepdegestrant的第3期临床试验的顶线数据，这是针对ER+/HER2-乳腺癌患者的唯一PROTAC® ER降解剂[2] - Arvinas计划在第二线设置中与CDK4/6抑制剂联合进行新的第3期试验，以及在第一线设置中进行vepdegestrant与辉瑞新型CDK4抑制剂的新的第3期试验，同时计划进行ARV-766的临床试验，并在B细胞淋巴瘤中进行BCL6靶向PROTAC®的第1期临床试验[38][39]

业绩总结 - Arvinas公司2023年第四季度和全年财务业绩表现良好[1] - Arvinas公司收到美国食品和药物管理局对vepdegestrant进行单药治疗的快速通道指定[2] - Arvinas公司与Pfizer合作共同开发和共同商业化vepdegestrant[35] 用户数据 - vepdegestrant和palbociclib组合队列的中期结果显示出令人鼓舞的临床活性[3] - vepdegestrant在肿瘤细胞中表现出高达97%的ER降解[35] 未来展望 - Arvinas公司致力于通过发现、开发和商业化降解致病蛋白的疗法来改善患有严重和危及生命的疾病的患者的生活[36] 新产品和新技术研发 - Arvinas公司在研发方面投入了大量资金，以推动新产品和新技术的研发[28] 市场扩张和并购 - Arvinas公司在2023年12月31日的现金、现金等价物、受限现金和可市场证券总额增加了55.7百万美元，显示出市场扩张的潜力[27]